AzTrials
AzTrials

InfectionPhase 4NCT04669353

Platelet Rich Plasma and Wound Healing After Cesarean Section

A Phase 4 study testing Platelet rich plasma in people with Infection, run by Menoufia University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Objective: To assess the effect of autologous Platelet Rich Plasma (PRP) on wound healing and pain perception in high risk women undergoing cesarean sections in a low resource setting. Read more about this study

Who is it for?
Ages 20 to 40 years, women only
Conditions the study is for
Infection
What is being tested?
Platelet rich plasma
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteEgypt
Study dates
1 Apr 2018to 30 Dec 2020
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 40 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Body mass index (BMI) > 30 kglcm2
  • prior cesarean section
  • pregestational or gestational diabetes
  • hypertensive disorders of pregnancy
  • placenta Previa
  • twin pregnancy
  • anemia
  • corticosteroid medication

Who cannot join

  • • chronic pain disorders
  • hepatitis
  • thrombocytopenia
  • coagulation disorders

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Menoufia university hospital

    Cairo

Other trials in Egypt

About this study

Official title: The Effect of Autologous Application of Platelet Rich Plasma on Wound Healing and Pain Perception After Cesarean Section in a Low Resource Setting

Objective: To assess the effect of autologous Platelet Rich Plasma (PRP) on wound healing and pain perception in high risk women undergoing cesarean sections in a low resource setting.

Methods: This was a randomized controlled trial of 200 women who attended the outpatient clinic of Menoufia University Hospital for elective cesarean surgery. The women were randomly assigned to two groups. The intervention group received PRP after surgery, whereas the control group received the usual care. Outcomes included Redness, Edema, Ecchymosis, Discharge, Approximation (REEDA) scale, Vancouver scar scale (VSS), and the visual analog scale (VAS).

Read the detailed description

The investigators conducted this randomized controlled trial from April 2018 to July 2020 at the Department of Obstetrics and Gynecology at Menoufia University Hospital, which is a large tertiary center in the Delta region in Egypt with a delivery rate of about 10000 per year. This study was approved by Menoufia university hospital ethical committee Institutional review board (198190PSGN33). The investigators obtained informed consent from all participants before initiating any study procedures. CONSORT guidelines were observed and completed.

The patients included in the study were between 20 and 40 years of age. Eligible women had one or more of the following risk factors: Body mass index (BMI) > 30 kglcm2, prior cesarean section, pregestational or gestational diabetes, hypertensive disorders of pregnancy, placenta Previa, twin pregnancy, anemia, and corticosteroid medication. Exclusion criteria were chronic pain disorders, hepatitis, thrombocytopenia, and coagulation disorders.

The investigators randomized participants in a 1:1 ratio to two equal groups containing one hundred patients each (intervention and control groups). A statistician not directly involved in the study prepared a computer generated randomization list and placed the allocation information in sequentially numbered sealed envelopes that were opened according to the attendance of the patients after signing the informed consent. The study authors were unaware of the envelope allocation sequence. Participants and outcome assessors did not know which group had been assigned to for the duration of the study.

In the operating room before the start of each procedure, approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate. After closure of the fascia and prior to skin closure, PRP was directly applied to the subcutaneous tissue of the wound site by using a sterile syringe. In the control group (group II), the patients did not receive topical treatment and the subcutaneous tissue was cleaned with normal saline before skin closure. For all patients, the skin was closed with polyprolene 2-0 suture with a curved cutting needle. The patients were examined by the physicians who were blinded to the group allocation on day 1, and then day 7 and 6 months after the procedure.

Pain was evaluated by the visual analog scale system (VAS) which assesses changes of pain via a continuous measurement instrument that is operationally comprised of a horizontal line, anchored at each end by verbal descriptors such as no pain and the worst pain imaginable. The subject is asked to indicate a spot on the scale that best represents her degree of pain. The score is determined by measuring the distance (mm) between the no pain anchor to the point that the patient marks, providing a range of scores from 0 - 10. A higher score indicates greater pain intensity.

The primary outcome was the Redness, Edema, Ecchymosis, Discharge, Approximation (REEDA) scale for assessing the changes in wound healing. REEDA as a descriptive scale has 4 points in a categorical score that measures 5 items of healing: redness (hyperemia), edema, ecchymosis, discharge, and approximation of the wound edges (coaptation). Each item is rated on a scale of 0 to 3, and total scores may range from 0 to 15. A lower score indicates better healing.

The secondary outcomes were measured by Vancouver scar scale (VSS) and VAS. VSS use to detect changes of formation of keloids or hypertrophic scars. It assesses 4 subjective variables: vascularity, height/thickness, pliability, and pigmentation within a possible range of 0 - 14 for the total score.

The sample size was calculated by using Epi-Info program version 3.5.4 by adjusting confidence interval to 95%. With an alpha error of 5% and study power of 80% and assuming a clinically relevant reduction in REEDA and VSS scores based on results of previous studies, the invesigators estimated a total sample size of 182 women (91 for each group). This was increased to 200 women considering about 10% drop out rate. The data collected, were tabulated and analyzed by SPSS (statistical package for the social science software) statistical package version 20 (Chicago Inc., USA), the following tests were used; Quantitative data were expressed as mean and standard deviation (X ± SD) and analyzed by applying student t test. Qualitative data were analyzed by Chi Square test. P-value at 0.05 was used to determine significance regarded as non-significant P> 0.05, significant P≤ 0.05 or highly significant P≤ 0.001.

Conditions
Infection
Being tested
Platelet rich plasma
Keywords
Platelet Rich Plasma, wound Healing, Pain, Cesarean Section
Medical subject headings
Infections, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Platelet rich plasmaDrug

    approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate.

Study groups in NCT04669353
Study groupRoleWhat they receive
Platelet Rich PlasmaActive comparatorIn the operating room before the start of each procedure, approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate. After closure of the fascia and prior to skin closure, PRP was directly applied to the subcutaneous tissue of the wound site by using a sterile syringe.
Receives: Drug: Platelet rich plasma
control groupNo interventionIn the control group (group II), the patients did not receive topical treatment and the subcutaneous tissue was cleaned with normal saline before skin closure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Redness, Edema, Ecchymosis, Discharge, Approximation scale changes

    for assessing the changes in wound healing. REEDA as a descriptive scale has 4 points in a categorical score that measures 5 items of healing: redness (hyperemia), edema, ecchymosis, discharge, and approximation of the wound edges (coaptation). Each item is rated on a scale of 0 to 3, and total scores may range from 0 to 15. A lower score indicates better healing

    Measured: day 1, day 7 and 6 months

Secondary outcomes (2)
  1. Vancouver scar scale changes.

    Vancouver scar scale (VSS) use to detect changes of formation of keloids or hypertrophic scars. It assesses 4 subjective variables: vascularity, height/thickness, pliability, and pigmentation within a possible range of 0 - 14 for the total score. A lower score indicates better healing.

    Measured: day 1, day7, and 6 months

  2. Visual Analog Scale changes

    Pain was evaluated by the visual analog scale system (VAS) which assesses changes of pain via a continuous measurement instrument.The score is determined by measuring the distance (mm) between the no pain anchor to the point that the patient marks, providing a range of scores from 0 - 10. A higher score indicates greater pain intensity

    Measured: day 1, day7, and 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2020
  2. Study start1 Apr 2018
  3. Primary completion1 Jul 2020
  4. Study completion30 Dec 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04669353
Sponsor's protocol ID
198190PSGN33
Status last verified
Aug 2021
First submitted
6 Dec 2020
Last updated
18 Aug 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Platelet rich plasma in people with Infection, run by Menoufia University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Redness, Edema, Ecchymosis, Discharge, Approximation scale changes (time frame: day 1, day 7 and 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in